Glenmark gets USFDA nod to market generic drug for muscle pain

Glenmark gets USFDA nod to market generic drug for muscle pain

Business


Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food and Drug Administration (USFDA) for Chlorzoxazone tablets USP, in strength of 375 mg and 750 mg, the drug maker said in a statement.


Glenmark Pharmaceuticals on Wednesday said its subsidiary has received approval from the US health regulator to market Chlorzoxazone tablets, used to treat muscle pain, in the American market.

Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food and Drug Administration (USFDA) for Chlorzoxazone tablets USP, in strength of 375 mg and 750 mg, the drug maker said in a statement.

This marks company’s first abbreviated new drug application (ANDA) approval out of its new North American manufacturing facility based in Monroe, North Carolina, it added.

According to IQVIATM sales data, for the 12 month period ending March 2020, the Chlorzoxazone had annual sales of around USD 20.9 million.

Glenmark’s current portfolio now consists of 163 products authorised for distribution in the US while 45 ANDAs are pending with the USFDA, the company said.

In addition to these internal filings, the company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, it added.

Moneycontrol Ready Reckoner

Now that payment deadlines have been relaxed due to COVID-19, the Moneycontrol Ready Reckoner will help keep your date with insurance premiums, tax-saving investments and EMIs, among others.

Get best insights into Options Trading. Join the webinar by Mr. Vishal B Malkan on May 28 only on Moneycontrol. Register Now!

First Published on May 27, 2020 10:59 am





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *